Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: An immunohistochemical study correlating grading, staging, and proliferation markers

Cancer

Volumn 85, Issue 7, 1999, Pages 1593-1598

  Haitel, Andrea ^a   Wiener, Helene G ^a   Blaschitz, Ulrike ^a   Marberger, Michael ^a   Susani, Martin ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immunohistochemistry; Multifocality; p53; Proliferation; Renal cell carcinoma

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033121112     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1593::AID-CNCR22>3.0.CO;2-K     Document Type: Article

References (27)

1. Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 1984;38:119-26.
2. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994; 86:1470-5.
3. Bot FJ, Godschalk JCJ, Krishnadath KK, Van der Kwast THM, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994;57:634-7.
4. Lipponen P, Eskelinen M, Hietala K, Syrjänen K, Gambetta RA. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erb B-2 in renal adenocarcinoma. Int J Cancer 1994;57:275-80.
5. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
6. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours. 5th edition. New York: Wiley-Liss, Inc., 1997:180-2.
7. Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma. Cancer 1997;80:987-9.
8. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 1993;22:355-60.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
11. Kletscher BA, Qian J, Bostwick D, Andrews PE, Zincke H. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume, and deoxyribonucleic acid ploidy. J Urol 1995;153: 904-6.
12. Nissenkorn I, Bernheim J. Multicentricity in renal cell carcinoma. J Urol 1995;153:620-2.
13. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994;172:1-4.
14. Sanchez Y, Elledge SJ. Stopped for repairs. BioEssays 1995; 17:545-8.
15. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995;55:658-62.
16. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon D, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994;7:766-70.
17. Kamel D, Turpeenniemi-Hujanen T, Vähäkangas K, Pääkkö P, Soini Y. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histopathology 1994;25: 339-47.
18. Henn W, Zwergel T, Wullich B, Thönnes M, Zang KD, Seitz G. Bilateral multicentric papillary renal tumors with heteroclonal origin based on tissue-specific karyotype instability. Cancer 1993;72:1315-8.
19. Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, van Heerden JA, et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 1991;87:1691-9.
20. Haerslev T, Jacobsen GK. An immunohistichemical study of p53 with correlations to histopathological parameters, c-erb B-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 1995;26:296-301.
21. Korkolopoulou P, Oates J, Crocker J, Edwards C. p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen. J Clin Pathol 1993;46:1093-6.
22. Schimmelpenning H, Eriksson ET, Zetterberg A, Auer G. Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas. World J Surg 1994;18:827-33.
23. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992;45:416-9.
24. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G. p53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995;75:87-93.
25. Golouh R, Bracko M, Novak J. Predictive value of proliferation-related markers, p53, and DNA ploidy for survival in patients with soft tissue spindle-cell sarcomas. Mod Pathol 1996;9:919-24.
26. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53. Proc Natl Acad Sci 1996;93:895-9.
27. Haitel A, Wiener HG, Migschitz B, Marberger M, Susani M. Proliferating cell nuclear antigen and MIB-1: an alternative to classic prognostic indicators in renal cell carcinomas? Am J Clin Pathol 1997;107:229-35.